Editas Medicine (EDIT) News
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.90+0.06 (+2.11%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 2.86 -1.38%
EDIT news summary
We found 2 recent headlines mentioning Editas Medicine (EDIT): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, EDIT is up 2.11% at $2.90. The most recent story, "Wells Fargo Upgrades Editas Medicine to Overweight from Equal-Weight", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Editas Medicine headlines
- Wells Fargo Upgrades Editas Medicine to Overweight from Equal-WeightFintel reports that on October 8, 2026, Wells Fargo upgraded their outlook for Editas Medicine (NASDAQGS:EDIT) (LSE:0IFK) from Equal-Weight to Overweight.Editas Medicine, Inc., based in the United…Nasdaq
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with HyperlipidemiaPhase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C loweringGlobeNewswire